Citations 5
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
Bantilan, Kurt S. , Smith, Alexandra N., Maurer, Matthew J. , Teruya‐Feldstein, Julie , Matasar, Matthew J. , Moskowitz, Alison J. , Straus, David J. , Noy, Ariela , Palomba, M. Lia , Horwitz, Steven M. , Portlock, Carol S., Nowakowski, Grzegorz S. , Moskowitz, Craig H. , Hamlin, Paul A , Cerhan, James R , Salles, Gilles A , Nowakowski, Grzegorz S , Zelenetz, Andrew D , Maurer, Matthew , Horwitz, Steven M , Matasar, Matthew , Noy, Ariela , Cerhan, James R. , Habermann, Thomas M. , Salles, Gilles , Zelenetz, Andrew D.
Blood Advances | January 25, 2024 | Volume: 8 | Issue: 9 | Pages: 2172-2181
10.1182/bloodadvances.2023011408
Abstract Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered the standard-of-care for patients with advanced-stage diffuse large B-cell lymphoma (DLBCL), despite findings that patients with nongerminal center B-cell like (non-GCB) have significantly worse outcome with this regimen. We evaluated the prognostic significance of baseline risk factors, including cell of origin (COO) classified by the Hans algorithm, within an alternative chemoimmunotherapy program. At Memorial Sloan Kettering Cancer Center (MSK), 151 patients with DLBCL received sequential R-CHOP induction and (R)-ICE (rituximab, ifosfamide, carboplatin, and etoposide) consolidation. Outcome analysis based on COO was validated with a propensity score–matched cohort treated with R-CHOP from the Mayo Clinic component of the Molecular Epidemiology Resource (MER). Among the patients with GCB (n = 69) and non-GCB (n = 69) at MSK, event-free survival (EFS) of non-GCB was superior to that of GCB (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.29-0.98). Overall survival (OS) demonstrated an association in the same direction but was not statistically significant (HR, 0.68; 95% CI, 0.33-1.42). Propensity score–matched patients from MSK (n = 108) demonstrated a small attenuation in the HRs for EFS (HR, 0.57; 95% CI, 0.27-1.18) and OS (HR, 0.76; 95% CI, 0.33-1.79) and were no longer statistically significant. In contrast, the matched MER cohort (n = 108) demonstrated an EFS association (HR, 1.17; 95% CI, 0.70-1.95) and OS association (HR, 1.13; 95% CI, 0.64-2.00) in the opposite direction, but were also not statistically significant. R-CHOP induction and (R)-ICE consolidation may overcome the negative prognostic impact of the non-GCB phenotype, per the Hans algorithm, and can be preferentially selected for this population. This trial was registered at www.ClinicalTrials.gov as #NCT00039195 and #NCT00712582.
Hypomagnesemia and Prognosis in Newly Diagnosed Diffuse Large B Cell Lymphoma
Smith, Alexandra N., Ruan, Gordon, Abeykoon, Jithma P., McMahon, M. Molly , Gile, Jennifer , Maurer, Matthew J. , Abeykoon, Jithma P. , Witzig, Thomas E.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11919-11920
The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
Smith, Alexandra N., Ali, Najla Al , Coombs, Catherine C. , Foran, James M. , Tsai, Charlton , Amanam, Idoroenyi , Lai, Catherine , Deeg, Joachim, Dinner, Shira, Chandhok, Namrata S. , Soong, Deborah, Brunner, Andrew M. , Geyer, Susan M. , Padron, Eric , Patnaik, Mrinal M. , Al‐Kali, Aref , Xie, Zhuoer , Komrokji, Rami S. , Patel, Anand , Saygin, Caner , Zeidan, Amer M. , Bewersdorf, Jan Philipp , Kishtagari, Ashwin , Zeidner, Joshua F. , Madanat, Yazan F. , Badar, Talha , Desai, Pinkal , Griffiths, Elizabeth A. , Malki, Monzr M. Al , Lai, Catherine, Adès, Lionel , Yi, Cecilia Arana , Osman, Afaf E.G. , Abaza, Yasmin , Taylor, Justin , Carraway, Hetty E. , Singh, Abhay , Savona, Michael R.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2887-2890
FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
Flowers, Christopher R. , Villa, Diego , Weibull, Caroline E., Cahn, Elliot, Smith, Alexandra N., Ghesquières, Hervé , Kridel, Robert , Seymour, John F. , Freeman, Ciara L. , Friedberg, Jonathan W. , Móciková, Heidi , Fürst, Tomáš, Cohen, Jonathon B. , Lossos, Izidore S. , Smedby, Karin E. , El-Galaly, Tarec Christoffer Christoffer, Kridel, Robert , Maurer, Matthew J. , Procházka, Vít , Jakobsen, Lasse Hjort , Gandhi, Maher K. , Cheah, Chan Y. , Hawkes, Eliza A. , Clausen, Michael Roost , Wahlin, Björn , Casulo, Carla , Habermann, Thomas M. , Wang, Yucai , Nastoupil, Loretta J. , Brown, Peter de Nully , Belada, David , Janikova, Andrea , Burack, Richard , Martin, Peter, Kahl, Brad S. , Link, Brian K. , Sehn, Laurie H. , Trněný, Marek , El‐Galaly, Tarec Christoffer , Cerhan, James R.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2292-2295
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
Desai, Sanjal H. , Mwangi, Raphael , Smith, Alexandra N., King, Rebecca L. , Thompson, Carrie A. , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A , Wang, Yucai , Witzig, T.E. , Desai, Sanjal , Maurer, Matthew J. , Farooq, Umar , Cerhan, James R. , Feldman, Andrew L. , Habermann, Thomas M. , Wang, Yucai , Witzig, Thomas E.
Hematological Oncology | October 28, 2022 | Volume: 41 | Issue: 1 | Pages: 39-49
Abstract Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R‐CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well‐characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non‐GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI 95 : 38–54] vs. non‐GCB: 44% [CI 95 :36–55], p > 0.05) or GEP (2 years OS ABC: 42% [CI 95 : 29–59] vs. GCB: 40% [CI 95 : 30–54], p > 0.05), was not associated with difference in OS. DHL (2 years OS 16 [CI 95 :6–45] vs. 45% [CI 95 : 34–59], p < 0.01) and DEL (2 years OS 33% [CI 95 : 20–56], vs. 50% [CI 95 : 41–60], p < 0.05) had lower OS than non‐DHL and non‐DEL/non‐DHL counterparts, respectively. COO by IHC or GEP was not associated with OS in R/R DLBCL while DHL and DEL were adverse prognostic markers in DLBCL at first relapse.